Omeros Stock Today
| OMER Stock | USD 11.91 0.24 1.98% |
Performance16 of 100
| Odds Of DistressLess than 49
|
Omeros is selling at 11.91 as of the 29th of November 2024; that is 1.98% down since the beginning of the trading day. The stock's lowest day price was 11.27. Omeros has 49 percent odds of going through some form of financial distress in the next two years but had a very solid returns during the last 90 days. Equity ratings for Omeros are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 8th of October 2009 | Category Healthcare | Classification Health Care |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company has 57.95 M outstanding shares of which 10.73 M shares are now shorted by private and institutional investors with about 11.99 trading days to cover. More on Omeros
Moving together with Omeros Stock
| 0.64 | FNMFO | Federal National Mortgage Upward Rally | PairCorr |
Moving against Omeros Stock
Omeros Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Catherine Melfi | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOmeros can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Omeros' financial leverage. It provides some insight into what part of Omeros' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Omeros (OMER) is traded on NASDAQ Exchange in USA. It is located in The Omeros Building, Seattle, WA, United States, 98119 and employs 198 people. Omeros is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 690.18 M. Omeros conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 57.95 M outstanding shares of which 10.73 M shares are now shorted by private and institutional investors with about 11.99 trading days to cover.
Omeros currently holds about 122.56 M in cash with 74.73 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.95.
Check Omeros Probability Of Bankruptcy
Ownership AllocationOmeros owns a total of 57.95 Million outstanding shares. 30% of Omeros outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Omeros Ownership Details
Omeros Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-09-30 | 509.5 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 485 K | |
| Ubs Group Ag | 2024-06-30 | 482.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 394.7 K | |
| Nomura Holdings Inc | 2024-06-30 | 394.5 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 218.6 K | |
| First Trust Advisors L.p. | 2024-06-30 | 162.8 K | |
| Bridgeway Capital Management, Llc | 2024-09-30 | 161.3 K | |
| Susquehanna Fundamental Investments, Llc | 2024-06-30 | 156 K | |
| Ingalls & Snyder Llc | 2024-09-30 | 4.5 M | |
| Blackrock Inc | 2024-06-30 | 4.1 M |
Omeros Historical Income Statement
Omeros Stock Against Markets
Omeros Corporate Management
| Peter JD | General VP | Profile | |
| Michael Jacobsen | Principal Financial Officer, Chief Accounting Officer, VP of Fin. and Treasurer | Profile | |
| Nadia Dac | VP Officer | Profile | |
| Debra MT | Chief Officer | Profile | |
| Andreas MD | Chief Officer | Profile | |
| Gregory MD | Chairman, CoFounder | Profile |
Additional Tools for Omeros Stock Analysis
When running Omeros' price analysis, check to measure Omeros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omeros is operating at the current time. Most of Omeros' value examination focuses on studying past and present price action to predict the probability of Omeros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omeros' price. Additionally, you may evaluate how the addition of Omeros to your portfolios can decrease your overall portfolio volatility.